Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations

Yanhui Lu, Connie Celum, Anna Wald, Jared M. Baeten, Frances Cowan, Sinead Delany-Moretlwe, Stewart E. Reid, James P. Hughes, Ellen Wilcox, Lawrence Corey, Craig W. Hendrix

Research output: Contribution to journalArticlepeer-review

Abstract

Acyclovir pharmacokinetics was evaluated in 68 HIV-seronegative, herpes simplex virus 2 (HSV-2)-seropositive African women, who received a single oral 400-mg dose of acyclovir, with plasma acyclovir concentrations measured over 8 h. Geometric mean peak concentration and area under the concentration-time curve were 0.31 μg/ml and 1.59 h · μg/ml, respectively, 54% and 52% lower than values from non-Africans. Lower acyclovir concentrations may partly explain the reduced acyclovir suppression of HSV-2 genital ulcer recurrence in HPTN 039 African women participants.

Original languageEnglish (US)
Pages (from-to)2777-2779
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume56
Issue number5
DOIs
StatePublished - May 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations'. Together they form a unique fingerprint.

Cite this